Zomedica Historical Income Statement
| ZOM Stock | USD 0.12 0.01 7.69% |
Historical analysis of Zomedica Pharmaceuticals income statement accounts such as Interest Expense of 183.8 K, Selling General Administrative of 30.5 M, Other Operating Expenses of 59.6 M or Total Operating Expenses of 51.4 M can show how well Zomedica Pharmaceuticals Corp performed in making a profits. Evaluating Zomedica Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Zomedica Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Zomedica Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Zomedica Pharmaceuticals is a good buy for the upcoming year.
Zomedica |
About Zomedica Income Statement Analysis
Zomedica Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Zomedica Pharmaceuticals shareholders. The income statement also shows Zomedica investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Zomedica Pharmaceuticals Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Zomedica Pharmaceuticals. It is also known as Zomedica Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Zomedica Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Zomedica Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. At this time, Zomedica Pharmaceuticals' Cost Of Revenue is very stable compared to the past year. As of the 11th of December 2024, Interest Income is likely to grow to about 5.9 M, though EBIT is likely to grow to (33.9 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 1.1M | 4.0M | 6.3M | 6.6M | Interest Income | 321.1K | 2.5M | 5.6M | 5.9M |
Zomedica Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Zomedica Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Zomedica Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 18.3K | 732.0 | 6.1K | 1K | 175K | 183.8K | |
| Selling General Administrative | 8.2M | 7.9M | 22.7M | 22.9M | 29.0M | 30.5M | |
| Other Operating Expenses | 19.8M | 16.8M | 25.5M | 40.9M | 56.8M | 59.6M | |
| Operating Income | (19.8M) | (16.8M) | (21.4M) | (21.9M) | (31.6M) | (30.0M) | |
| Ebit | (19.8M) | (16.9M) | (20.7M) | (19.4M) | (35.7M) | (33.9M) | |
| Ebitda | (19.0M) | (16.4M) | (19.6M) | (15.3M) | (29.4M) | (27.9M) | |
| Total Operating Expenses | 19.8M | 16.8M | 24.4M | 35.6M | 48.9M | 51.4M | |
| Income Before Tax | (19.8M) | (16.9M) | (20.7M) | (19.4M) | (35.9M) | (34.1M) | |
| Net Income | (19.8M) | (16.9M) | (18.4M) | (17.0M) | (34.5M) | (32.8M) | |
| Gross Profit | (787.6K) | (530.0K) | 3.1M | 13.7M | 17.3M | 18.2M | |
| Net Income From Continuing Ops | (19.8M) | (16.9M) | (18.4M) | (17.0M) | (14.9M) | (15.7M) | |
| Research Development | 10.3M | 8.0M | 1.7M | 2.6M | 5.7M | 5.3M | |
| Cost Of Revenue | 787.6K | 530.0K | 1.1M | 5.3M | 7.9M | 8.3M | |
| Total Other Income Expense Net | 273.0 | (146.8K) | 657.8K | 2.5M | (4.3M) | (4.1M) | |
| Net Income Applicable To Common Shares | (19.8M) | (16.9M) | (18.4M) | (17.0M) | (15.3M) | (16.1M) | |
| Income Tax Expense | 38.1K | 9.3K | (2.3M) | (2.4M) | (1.3M) | (1.3M) | |
| Interest Income | 18.2K | 32.9K | 321.1K | 2.5M | 5.6M | 5.9M | |
| Depreciation And Amortization | 807.4K | 530.0K | 1.1M | 4.0M | 6.3M | 6.6M | |
| Reconciled Depreciation | 787.6K | 530.0K | 1.1M | 4.0M | 5.7M | 5.9M | |
| Non Operating Income Net Other | (1.1K) | (87.0K) | (760.4K) | (158K) | (142.2K) | (149.3K) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.06) | Revenue Per Share 0.027 | Quarterly Revenue Growth 0.018 | Return On Assets (0.09) | Return On Equity (0.24) |
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.